Archives of Clinical Infectious Diseases

Published by: Kowsar

Superoxide Dismutase B1, an Exacerbatory Antigen Elicits Interleukin-10 Production in Murine Leishmania major Infection

Farshid Yeganeh 1 , Fereidoun Mahboudi 2 , Nasser Gholijani 3 , Farzaneh Barkhordari 2 , Ghader Khalili 4 and Eskandar Kamali-Sarvestani 3 , 5 , *
Authors Information
1 Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Biotechnology Department, Pasteur Institute of Iran, Tehran, Iran
3 Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4 Immunology Department, Pasteur Institute of Iran, Tehran, Iran
5 Department of Immunology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
Article information
  • Archives of Clinical Infectious Diseases: February 28, 2019, 14 (1); e66622
  • Published Online: February 27, 2019
  • Article Type: Research Article
  • Received: January 23, 2018
  • Revised: November 3, 2018
  • Accepted: November 5, 2018
  • DOI: 10.5812/archcid.66622

To Cite: Yeganeh F, Mahboudi F, Gholijani N, Barkhordari F, Khalili G , et al. Superoxide Dismutase B1, an Exacerbatory Antigen Elicits Interleukin-10 Production in Murine Leishmania major Infection, Arch Clin Infect Dis. 2019 ; 14(1):e66622. doi: 10.5812/archcid.66622.

Copyright © 2019, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5). e35671. doi: 10.1371/journal.pone.0035671. [PubMed: 22693548]. [PubMed Central: PMC3365071].
  • 2. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives. J Am Acad Dermatol. 2015;73(6):897-908. quiz 909-10. doi: 10.1016/j.jaad.2014.08.051. [PubMed: 26568335].
  • 3. Kaye P, Scott P. Leishmaniasis: Complexity at the host-pathogen interface. Nat Rev Microbiol. 2011;9(8):604-15. doi: 10.1038/nrmicro2608. [PubMed: 21747391].
  • 4. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002;2(11):845-58. doi: 10.1038/nri933. [PubMed: 12415308].
  • 5. Sundar S, Singh B. Identifying vaccine targets for anti-leishmanial vaccine development. Expert Rev Vaccines. 2014;13(4):489-505. doi: 10.1586/14760584.2014.894467. [PubMed: 24606556]. [PubMed Central: PMC4040457].
  • 6. Rezvan H, Moafi M. An overview on Leishmania vaccines: A narrative review article. Vet Res Forum. 2015;6(1):1-7. [PubMed: 25992245]. [PubMed Central: PMC4405679].
  • 7. Ghosh S, Goswami S, Adhya S. Role of superoxide dismutase in survival of Leishmania within the macrophage. Biochem J. 2003;369(Pt 3):447-52. doi: 10.1042/BJ20021684. [PubMed: 12459037]. [PubMed Central: PMC1223130].
  • 8. Mehlotra RK. Antioxidant defense mechanisms in parasitic protozoa. Crit Rev Microbiol. 1996;22(4):295-314. doi: 10.3109/10408419609105484. [PubMed: 8989515].
  • 9. Yeganeh F, Barkhordari F, Omidi M, Samiei A, Adeli A, Mahboudi F, et al. Cloning and expression of Leishmania major superoxide dismutase B1: A potential target antigen for serodiagnosis of Leishmaniasis. Iran J Immunol. 2009;6(3):130-40. [PubMed: 19801786].
  • 10. Danesh-Bahreini MA, Shokri J, Samiei A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohammadi-Samani S. Nanovaccine for leishmaniasis: Preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int J Nanomedicine. 2011;6:835-42. doi: 10.2147/IJN.S16805. [PubMed: 21589651]. [PubMed Central: PMC3090280].
  • 11. Daifalla NS, Bayih AG, Gedamu L. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection. Exp Parasitol. 2012;131(3):317-24. doi: 10.1016/j.exppara.2012.05.002. [PubMed: 22580023].
  • 12. Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol. 2005;175(4):2517-24. doi: 10.4049/jimmunol.175.4.2517. [PubMed: 16081824].
  • 13. Cyktor JC, Turner J. Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens. Infect Immun. 2011;79(8):2964-73. doi: 10.1128/IAI.00047-11. [PubMed: 21576331]. [PubMed Central: PMC3147550].
  • 14. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest. 1993;92(1):324-9. doi: 10.1172/JCI116570. [PubMed: 8326000]. [PubMed Central: PMC293600].
  • 15. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007;28(9):378-84. doi: 10.1016/ [PubMed: 17689290].
  • 16. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol. 2001;166(2):1141-7. doi: 10.4049/jimmunol.166.2.1141. [PubMed: 11145695].
  • 17. Schwarz T, Remer KA, Nahrendorf W, Masic A, Siewe L, Muller W, et al. T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine. PLoS Pathog. 2013;9(6). e1003476. doi: 10.1371/journal.ppat.1003476. [PubMed: 23825956]. [PubMed Central: PMC3694851].
  • 18. Roberts MT, Stober CB, McKenzie AN, Blackwell JM. Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infect Immun. 2005;73(11):7620-8. doi: 10.1128/IAI.73.11.7620-7628.2005. [PubMed: 16239566]. [PubMed Central: PMC1273906].
  • 19. Nashed BF, Maekawa Y, Takashima M, Zhang T, Ishii K, Dainichi T, et al. Different cytokines are required for induction and maintenance of the Th2 type response in DBA/2 mice resistant to infection with Leishmania major. Microbes Infect. 2000;2(12):1435-43. doi: 10.1016/S1286-4579(00)01298-3. [PubMed: 11099930].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments